Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverFME.DE
HealthcareGEREUR

Fresenius Medical Care AG I

€0012345678900123456789.0012345678900123456789+0.7%
52w low (est.) €34.56€54.57 52w high (est.)
Market data · updated 1h ago
Peers
Market data
52w range
EUR34.57 - EUR47.86
Beta
0.82
Sector
Healthcare
Data quality
96/100
Valuation
P/E ratio
12.9x
DCF fair value
EUR27.79
Margin of safety
-35.8%
Forward P/E
9.6x
PEG ratio
0.85
Dividend yield
3.53%
Quality & efficiency
Moat score
24/100
Return on equity
7.9%
Profit margin
4.9%
Debt / equity
0.78
Growth & analysts
Revenue growth
-5.5%
Analyst target
EUR43.75
Target upside
+1.1%
Analysts
17
Run the 10-point checklist before you buy How these numbers are made

About Fresenius Medical Care AG I

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Valuation

ValueGrowthProfitHealthIncome38QUALITY
Overall Rating
32
Reduce
Reduce

Derived from filed metrics · High confidence (96% of the inputs available)

Moat Score24
DCF Intrinsic Value
EUR27.79-35.8% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
EUR0.00
P/E Ratio
12.9
Dividend Yield
3.53%
Revenue Growth
-5.5%
Profit Margin
4.9%
ROE
7.9%
Debt / Equity
0.78
Beta
0.82
ValueDividend Aristocrats
vs Healthcare sector:P/E 13 vs 28 · cheaperMoat 24 vs 7Yield 3.53% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · FME.DE